BioArctic AB

BioArctic is a Swedish research-based biopharmaceutical company. Founded in 2003 by Professor Lars Lannfelt and Dr. Pär Gellerfors, the company aims to develop Professor Lannfelt's significant breakthrough discoveries regarding Alzheimer's disease. These discoveries – the Swedish mutation and the Arctic mutation – have attracted widespread international attention and explained the central role of amyloid beta protein in Alzheimer’s disease, leading to the development of new therapeutic strategies. BioArctic has developed a proprietary technology platform, and the company's first Alzheimer's disease candidate antibody, BAN2401, has proven to be successful.